Keywords: spiriva, forecast, swallow, copd, market, boehringer, ingelheim
Spiriva forecast to swallow 45% of the COPD market in 2012
Article | 29 March 2004
Boehringer Ingelheim and Pfizer's Spiriva (tiotropium) will lead the chronic obstructive pulmonary disease market with a 45% share in 2012, according to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
